top of page

LET SCIENCE DO THE TALKING

 

We are a small molecule drug discovery and development biotech that uses a target-centric approach and classical medicinal chemistry to create new medicines

Metastatic melanoma cells

Photo by National Cancer Institute

CURADEV IN THE NEWS

Curadev Pharma receives FDA 'Study May Proceed' letter for its Investigational New Drug Application of CRD3874, an IV-Administered STING Agonist for the treatment of advanced/metastatic solid cancers

Mountains

ABOUT
US

We are a small molecule drug discovery and development biotech with an exciting portfolio of research programs that have yielded patent protected drug candidates. Founded in 2010, Curadev has created a premier translational research organization known for prescient target selection and high quality, data-driven program execution. Our programs seek to ameliorate disease by translating cutting edge discoveries into new medicines. We have swiftly established our credentials by successfully creating and out-licensing our small molecule patents to major pharmaceutical companies.

About us
bottom of page